In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China | Zendy

Ken B. Waites | Zendy; Donna M. Crabb | Zendy; Lynn B. Duffy | Zendy; Jørgen Skov Jensen | Zendy; Yang Liu | Zendy; Susanne Paukner | Zendy

Open Access

In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China

Author(s) -

Ken B. Waites,

Donna M. Crabb,

Lynn B. Duffy,

Jørgen Skov Jensen,

Yang Liu,

Susanne Paukner

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02008-16

Subject(s) - microbiology and biotechnology , erythromycin , mycoplasma pneumoniae , moxifloxacin , macrolide antibiotics , antimicrobial , azithromycin , tetracycline , doxycycline , biology , virology , antibiotics , medicine , pneumonia

Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistantMycoplasma pneumoniae strains, and the results were compared with those of azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active against all strains tested, with all MICs at ≤0.008 μg/ml. The lefamulin MIC90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research